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Abstract. 
XLF-Cernunnos (XLF) is a recently identified co-factor of the DNA Ligase IV/XRCC4 
(LX) complex, which functions in DNA non-homologous end joining (NHEJ). XLF has 
been reported to promote LX double stranded (ds) ligation activity by end-bridging. We 
show that XLF is a weaker binding partner of the tightly associated LX complex and, 
unlike XRCC4, is dispensable for LX stability. XLF enhances LX adenylation and 
strikingly promotes a three fold increase in the rate of LX re-adenylation following de-
adenylation by ligation, a reaction which is otherwise rate limiting. Whilst ATP alone 
fails to stimulate LX ds ligation activity, consistent with readenylation being rate limiting 
for ligation, addition of XLF and ATP promotes ligation. We also observe stimulation of 
LX activity by XLF in the absence of ATP, potentially attributable to end-bridging. 
Cellular analysis of 2BN cells, which do not express detectable XLF protein, show that 
they have a 3 fold decrease in DSB rejoining supporting our biochemical findings that 
XLF enhances NHEJ by promoting recycling of LX following ligation.  
 
Introduction. 
DNA non-homologous end-joining (NHEJ) is the major mechanism for the repair of 
radiation induced DNA double strand breaks (DSBs) in mammalian cells. Cell lines 
lacking components of the NHEJ machinery are exquisitely radiosensitive and DSB 
repair defective (Jeggo, 2005; Weterings and van Gent, 2004). NHEJ also functions to 
effect rearrangements at site specific DSBs introduced during the process of V(D)J 
recombination (Bassing and Alt, 2004; Gellert, 2002). Consequently, viable mice 
deficient in NHEJ proteins show severe combined immunodeficiency (SCID). Patients 
deficient in NHEJ components have also been described. Most patients show varying 
degrees of combined immunodeficiency, microcephaly and developmental delay and cell 
lines derived from them display radiosensitivity, leading to the classification of 
radiosensitive-(RS)-SCID (Buck et al., 2006; Dai et al., 2003; Moshous et al., 2001; 
O'Driscoll et al., 2001). One patient received radiotherapy and dramatically over-
responded to treatment demonstrating clinical radiosensitivity (Plowman et al., 1990; 
Riballo et al., 1999).  
The first step of NHEJ is binding of the heterodimeric Ku protein to double 
stranded (ds) DNA ends. The crystal structure of Ku has shown it to be a basket shaped 
structure with a central core surrounded by a base, a “handle” and two “pillars” (Walker 
et al., 2001). The central core is of sufficient diameter to allow the threading of Ku onto 
ds DNA and its translocation along the DNA. Once bound to DNA, Ku recruits the DNA-
PK catalytic subunit (DNA-PKcs), creating the active DNA-PK complex (Dvir et al., 
1992; Gottlieb and Jackson, 1993). Increasing evidence suggests that DNA-PK undergoes 
autophosphorylation, which serves to regulate the process and/or facilitate the 
recruitment of additional proteins required for end processing (Kurimasa et al., 1999). 
The assembled DNA-PK complex facilitates the recruitment of a ligation complex 
encompassing XRCC4 and DNA Ligase IV (Calsou et al., 2003; Nick McElhinny et al., 
2000).  
XLF-Cernunnos, hereafter called XLF, was identified via the analysis of one class 
of RS-SCID patients with features closely resembling those of LIG4 syndrome patients, a 
disorder caused by mutations in DNA Ligase IV (Ahnesorg et al., 2006; Buck et al., 
2006; Dai et al., 2003). This strongly suggested that XLF is a component of the NHEJ 
machinery, which is substantiated by the finding that XLF interacts with XRCC4 
(Ahnesorg et al., 2006). Interestingly, XLF is predicted to have a structure similar to 
XRCC4 with an N-terminal globular head domain and C-terminal coiled coil structure 
(Ahnesorg et al., 2006). Subsequent analysis revealed that XLF, in fact, represents the 
mammalian homologue of the yeast Nej1p protein, a factor regulating NHEJ in yeast, and 
that both proteins belong to an extended XRCC4 family (Callebaut et al., 2006).  Since 
both LIG4 and XLF deficient cell lines are proficient in Ku end-binding activity and 
display normal DNA-PK activity, the available evidence suggested that XLF is a further 
factor required for the ligation step of NHEJ (Ahnesorg et al., 2006; Dai et al., 2003). The 
co-immunoprecipitation of XLF with LX has lead to the suggestion of a tripartite XLF-
XRCC4-LigaseIV complex. Further studies have shown that XLF can stimulate LX 
ligation by promoting end-bridging (Ahnesorg et al., 2006; Gu et al., 2007; Hentges et al., 
2006). Since multiple proteins are able to promote end-bridging in vitro including DNA-
PKcs and Ku, and since DNA ends might be tethered to some extent by the higher order 
structure of DNA, we considered it unlikely that this would represent the marked in vivo 
role for XLF (Nagaki et al., 1998; Pil et al., 1993; Ramsden and Gellert, 1998; Stiff et al., 
2004) and therefore sought further evidence for the impact of XLF on LX activities.  
The ligation reaction involves an initial charging step involving the formation of a 
DNA Ligase IV-adenylate complex involving the catalytic lysine in DNA Ligase IV. LX 
complexes are expressed in baculovirus, bacteria and human cells as an adenylate 
complex. The ligation reaction involves transfer of the AMP moiety to the 5’ phosphate 
on the DNA creating a DNA-adenylate complex and releasing uncharged DNA Ligase 
IV, which needs to be re-adenylated for subsequent ligation activity. A recent study 
characterising LX based on its nick ligation activity highlighted that, in contrast to other 
DNA Ligases, LX re-adenylation following ligation proceeds very slowly and is a rate 
limiting step in vitro (Wang et al., 2007).  In support of this, we and others have shown 
that the presence of ATP does not stimulate ds ligation suggesting that recharging of 
DNA Ligase IV does not occur efficiently. Here, we use biochemical and cellular 
approaches to probe the role of XLF in NHEJ. Analysis of an XLF deficient cell line, 
2BN, demonstrated that XLF is dispensable for Ligase IV stability and is a weaker 
binding partner of the LX complex. We show that XLF promotes a three-fold stimulation 
of LX re-adenylation following ligation. Consistent with these findings, we show that 
XLF stimulates LX activity in the presence of ATP. Examination of XLF deficient 2BN 
cells provides an explanation for the overlapping clinical features of XLF and DNA 
ligase IV deficient patients.  Collectively, our data suggest that XLF is facilitating but 
non-essential for DSB repair by promoting recharging of LX following ligation, an 
activity that will benefit ds ligation.  
Results. 
XLF is dispensable for DNA ligase IV stability and is a weaker binding partner of 
the stable LX complex. 
To gain insight into XLF function in vivo, we used the 2BN cell line, which was derived 
from a severe combined immunodeficiency (SCID) patient with a single base pair (+T) 
insertion at position 11 (11insT) in the first coding exon of the XLF gene. The insertion 
creates a termination codon at position 139 (Ahnesorg et al., 2006; Dai et al., 2003). 
Using polyclonal antibodies raised to bacterially expressed, full length, human XLF 
protein (α-XLF), we were unable to detect any residual XLF protein in 2BN cell extracts 
by immunofluorescence or immunoblotting (Figures 1A and B) despite a strong signal 
obtained by immunoblotting control cell extracts consolidating previous analysis of 2BN 
cells using a distinct α-XLF antibody (Ahnesorg et al., 2006). We were also unable to 
detect any smaller fragments in the immunoblots in 2BN cells providing no evidence that 
translational reinitiation occurs in 2BN cells (results not shown). Given the lack of any 
significant expression of XLF in 2BN cells, we examined the interdependence of XLF, 
XRCC4 and DNA Ligase IV expression and protein stability. Western blotting and 
immunofluorescence analysis showed that XRCC4 and DNA Ligase IV are expressed 
normally and localise to the nucleus in 2BN cells (Figures 1A and B). In contrast, XR-1 
cells, which lack XRCC4, express low levels of DNA Ligase IV, as reported previously 
(Figure 1B) (Bryans et al., 1999). Moreover, XRCC4 expression in a LIG4 null cell line, 
N114P2, is approximately one third reduced compared to the parent line, Nalm6 (Figure 
1B). XLF was expressed normally in DNA Ligase IV-defective N114P2 cells. The 
expression of XLF in the absence of XRCC4 in XR-1 cells could not be assessed since 
the α-XLF antibodies do not cross react with hamster XLF. Collectively, these findings 
demonstrate that, whereas XRCC4 and DNA Ligase IV are co-dependent for normal 
expression, XLF is dispensable for the stability of both XRCC4 and DNA Ligase IV. 
Conversely, DNA Ligase IV is dispensable for XLF stability and nuclear localisation. 
 Since the tightly associated LX complex is stable under high ionic strength, we 
examined the stability of the XLF-LX complex. We examined the impact of ionic 
strength on the interaction between DNA Ligase IV, XRCC4 and XLF using cell extracts 
derived from MRC5BIVA cells expressing N-terminal FLAG-tagged XLF (N-FLAG-
XLF). α-FLAG antibodies efficiently co-immunoprecipitated DNA Ligase IV under 
physiological salt conditions (0.12 M NaCl) but the interaction was substantially reduced 
at 0.5 M NaCl and essentially abolished at 1 M NaCl (Figure1C). This contrasts with the 
strong interaction between XRCC4 and DNA Ligase IV which is stable even at 1 M NaCl 
(Grawunder et al., 1997). We also examined interaction following expression of S35-
methionine radiolabelled, tagged proteins (HIS-LigIV; MYC-XRCC4 and FLAG-XLF) 
in a transcription-translation system (Figure 1D).  Immunoprecipitation using α-MYC 
antibodies efficiently co-immunoprecipitated XLF at 0.12 mM NaCl but not at 1 M NaCl. 
In contrast, DNA Ligase IV was efficiently co-immunoprecipitated using α-MYC 
antibodies under physiological and high salt conditions. XLF also co-immunoprecipitated 
with XRCC4 in the absence of DNA ligase IV, consistent with previous findings that the 
interaction is via XRCC4 (Ahnesorg et al., 2006).  
Altogether, these data show that, whereas XRCC4 tightly interacts with DNA 
Ligase IV enhancing its stable expression, the interaction between LX and XLF is 
considerably weaker. Thus, despite their predicted structural similarity, XLF cannot 
substitute for XRCC4 in stabilising DNA Ligase IV. These findings show that the LX 
complex represents a functional heterodimer with XLF representing a weaker binding 
partner. 
 
XLF stimulates Ligase IV re-adenylation following ligation. 
XLF has been reported to promote LX ligation activity by end-bridging (Ahnesorg et al., 
2006; Gu et al., 2007; Hentges et al., 2006). However, since multiple proteins stimulate 
LX activity by end-bridging, including Ku, DNA-PKcs, HMG proteins and AHNAK, we 
examined further the impact of XLF on LX functions. The first step of the ligation 
reaction is binding of AMP to the active site lysine of DNA Ligase IV. We examined 
whether XLF might affect LX adenylation activity. Since we were unable to purify a co-
expressed trimeric complex due to the weak association of XLF with LX at greater than 
physiological salt, we used separately purified, bacterially expressed XLF and insect cell 
expressed LX. We considered this reasonable given the nature of the interactions 
described above. LX is expressed in baculovirus as a pre-adenylate complex and 
assessment of adenylation activity is normally carried out following de-adenylation using 
high concentrations of inorganic pyrophosphate (PPi) which causes release of the AMP 
moiety. Using 5 pmols of XLF and 1 pmol of LX, we observed a 2-3 fold stimulation in 
the overall rate of adenylation over the course of 20 minutes (Figure 2A). A similar 
degree of stimulation was observed using between 5 and 30 pmols XLF. 
 We and others have previously been unable to observe re-adenylation of LX 
following ligation, consistent with the inability of ATP to stimulate LX in ligation assays 
(Riballo et al., 2001; Wang et al., 2007).  Therefore, we considered the possibility that 
XLF might play a role in recharging LX following ligation. To investigate this, we first 
examined the impact of ligatable DNA on the adenylation reaction using LX complexes 
that had been previously de-adenylated following PPi treatment. We utilised a 445bp 
pBluescript fragment that we have previously used in ds ligation reactions (Riballo et al., 
2001) and observed that the presence of DNA decreases adenylate complex formation 
regardless of the presence of XLF (Figure 2B). This suppressive impact was more 
marked at later times, consistent with the possibility that the act of ligation causes de-
adenylation of LX thereby reducing the overall amount of adenylate complex observed.  
 To determine whether XLF might stimulate re-adenylation following ligation, we 
adapted our assay to examine adenylate complex formation without prior de-charging of 
LX complexes by PPi treatment. In fact, we examined whether ligation was able to de-
charge the LX complexes allowing subsequent re-adenylation. To achieve this, we 
allowed ligation to take place in the absence of ATP, with or without XLF during a 15 
minute pre-incubation period, prior to the addition of radiolabelled ATP used to monitor 
adenylate complex formation (Figure 2C). Strikingly, we observed that XLF promoted 
LX adenylation following incubation in the presence of DNA, while no such activity was 
observed in the absence of XLF. This provides the first demonstration that re-adenylation 
of LX can occur following ligation. To verify that ligation had taken place during the 
reaction above, we monitored ligation during the pre-incubation phase in the absence of 
ATP and subsequently when ATP (with or without XLF) was added (Figure 2D). We 
could observe ligation products during the pre-incubation reaction consistent with the 
notion that de-adenylation occurred as a consequence of ligation during this pre-
incubation step. However, ligation reached a maximum at 15 min and further stimulation 
following the addition of ATP was not observed either in the presence or absence of 
XLF. This is likely due to the fact that only a small fraction of the LX complexes become 
recharged during the reaction since optimisation of our ability to detect LX-32P-adenylate 
complex formation required using radiolabelled ATP without any added cold ATP. Thus, 
the ATP concentrations are likely below the optimal Km for ATP for DNA Ligase IV. 
The presence of XLF during the 15 minutes pre-incubation step did not increase either 
the rate of LX adenylation (Figure 2C) or the level of ligation (data not shown), 
suggesting that XLF may not enhance ligation without prior de-adenylation of LX. 
However, in this experiment an excess of LX to substrate (5:1) was utilised, potentially 
limiting any ability to detect XLF stimulatory activity. We, therefore, modified the assay 
to examine the impact of XLF on ligation under LX rate-limiting conditions (1:4 ratio of 
LX to DNA ends) but still failed to observe any marked stimulation (Figure 2E). Thus, 
these findings show that while XLF does not markedly stimulate ligation during the pre-
incubation phase, it markedly enhances the rate of adenylation. Thus, we demonstrate 
that there is an impact on LX re-charging that cannot be attributed to any marked impact 
of XLF on ligation. 
Finally, we aimed to determine whether XLF was able to stimulate LX 
adenylation using physiologically relevant ratios of XLF and LX. To achieve this, we 
used α-XRCC4 antibodies to immunoprecipitate LX-XLF complexes from whole cell 
extracts using 0.12 M NaCl and employed a high salt (1M NaCl) wash to discharge XLF 
(Figure 1C). De-adenylation of the complexes was carried out by PPi treatment or by 
incubation with DNA. XLF stimulated LX adenylation activity following PPi treatment 
(+PPi, 1M NaCl versus +PPi, 0.12M NaCl) but strikingly, stimulation was even greater 
when DNA was used to de-charge the LX complexes (+DNA, 1 M NaCl versus + DNA, 
0.12M NaCl). Thus, even though our biochemical studies required a ratio of XLF to LX 
greater than one, potentially due to a percentage of inactive XLF in the XLF preparations, 
the ratio of XLF to LX obtained by co-immunoprecipitation was able to stimulate LX re-
adenylation linked to ligation.  
 
ATP-dependent and -independent stimulation of LX double stranded ligation by 
XLF.  
Previous studies have shown that XLF stimulates LX ds ligation activity (Gu et al., 2007; 
Hentges et al., 2006). Our finding that XLF stimulates recharging of LX following 
ligation predicted that XLF stimulation of ligation should be ATP dependent. Although 
we were unable to observe XLF stimulation of ligation in the experiments described 
above (Figure 2D), this was potentially attributable to the low ATP concentrations 
utilised. We, therefore, examined the impact of physiological ATP concentrations on the 
ability of XLF to stimulate LX ds ligation. Firstly, we titrated the amount of XLF 
stimulating 125 fmoles LX, which effects only a low level of ligation in our assay (Figure 
3A). We observed a broad peak of stimulation from 2.5-30 pmol XLF, which varied 
slightly with individual LX preparations. We next examined the ability of 17 pmols XLF 
to stimulate ligation effected by differing amounts of LX in the presence and absence of 
ATP (Figure 3B). In the absence of XLF, little ds ligation was observed. In agreement 
with previous findings and the discussion above, addition of ATP did not stimulate LX 
activity consistent with the notion that LX is not subject to re-adenylation following 
ligation (Figure 3B, compare left and right panels) (Riballo et al., 2001; Wang et al., 
2007). XLF provided some stimulation in the absence of ATP but further stimulation was 
observed in the presence of ATP (Figure 3B right panel). Significantly, when very high 
amounts of LX were employed (50 fmols), XLF provided no further stimulatory effect.  
It has been suggested that XLF might function as a bridging factor to facilitate the 
alignment and rejoining of ds DNA ends (Hentges et al., 2006; Lu et al., 2007). To 
examine this, we used a pull-down assay in which the 445 bp duplex substrate used for 
ligation was biotin labelled and bound to magnetic streptavidin beads together with XLF 
and an equal amount of an identical, 32P-end labelled substrate. Intermolecular 
association of the two substrates was assessed by monitoring the ability of the 
streptavidin beads to retain the 32P-labelled duplex following multiple wash steps (Figure 
3C). XLF significantly enhanced the recovery of radio-labelled DNA associated with 
beads demonstrating that it facilitates DNA end-bridging. As a control, we carried out the 
reaction using purified DNA-PK, which also promotes end-bridging (Cary et al., 1997; 
Merkle et al., 2002).  Mol for mol, DNA-PK had a greater level of duplex-bridging 
activity compared to XLF and, importantly, the addition of XLF together with DNA-PK 
was not additive. These findings are consistent with the notion that XLF promotion of 
ligation in the absence of ATP might be attributable to its ability to promote end-
bridging. It is noteworthy that the experiments carried out in Figure 2D used a lower XLF 
to LX molar ratio (~5:1), which was optimal for observing the stimulatory effect of XLF 
on LX adenylation. In contrast, the ligation experiments in Figure 3B required a higher 
molar ratio of XLF to LX (~75:1). Since the ratio of LX to DNA ends remains essentially 
the same between Figures 2D and 3B (~5:1 versus ~2:1, respectively), it is possible that 
the higher level of XLF is required to promote sufficient DNA end bridging to observe 
and effect. Since multiple proteins promote end-bridging and stimulate in vitro ligation 
reactions, it is currently unclear whether this represents a significant role for XLF under 
physiological conditions although it may provide an additional impact on ligation.  
The ATP-dependent impact of XLF is more unique, however, and consistent with 
the notion that XLF promotes recharging of LX. To further examine this, we also looked 
at the impact of XLF on the kinetics and maximal level of ligation with or without ATP 
(Figure 3D). In the absence of ATP, stimulation of ligation by XLF occurred within the 
first 3 minutes and little further stimulation was observed. Addition of ATP in the 
presence of XLF did not further enhance the initial rate of the ds ligation but dramatically 
enhanced the maximal level obtained. Taken together, we conclude that XLF stimulates 
ds LX ligation activity in two ways, one being ATP-independent and the other ATP-
dependent. In the presence of ATP, XLF enhances the maximal level of ligation 
consistent with our findings that it promotes recharging of LX following ligation.  
 
2BN cells show a three fold slower rate of DSB rejoining. 
Despite the very different impacts of XLF and LX on ligation, with LX being essential 
and XLF providing a modest stimulation, patients with mutations in XLF and DNA ligase 
IV have overlapping clinical features. To gain in vivo evidence for the impact of the loss 
of XLF function on ds ligation, we examined DSB rejoining in 2BN cells. Our findings in 
Figure 1A and B demonstrate that 2BN cells do not express detectable full length XLF 
protein, consistent with the 1 bp insertion in the cDNA. Even if there was a low level of 
read through of the termination codon generated at position 139, the majority of the 
cDNA would be out of frame and likely non-functional. However, one route that could 
potentially lead to residual activity is the possible use of in frame translational initiation 
codons producing a C-terminal fragment. Using polyclonal antibodies raised to 
bacterially-expressed full length human XLF protein (α-XLF), we did not detect 
expression of a smaller fragment in 2BN cell extracts of the anticipated size (data not 
shown). To examine further whether a downstream initiation codon might be utilised, we 
transfected wild type or mutant C-terminal HA-tagged XLF cDNA (C-HA-XLFWT or C-
HA-XLF11insT) into MRC5VIBA cells and examined protein expression using α-XLF and 
α-HA antibodies from cell extracts or following immunoprecipitation using α-HA 
antibodies. Transfection with C-HA-XLFWT cDNA resulted in expression of XLF 
detectable using α-XLF and α-HA antibodies, either with or without α-HA 
immunoprecipitation. No residual XLF protein or any smaller fragments were detectable 
following transfection with C-HA-XLF11insT cDNA (Figure 4A). Indeed, the only bands 
present were those observed using an empty vector expressing HA alone. We conclude 
that there is unlikely to be significant expression of C-terminal XLF fragments in 2BN 
cells.  
Taken together, these findings provide strong evidence that 2BN cells are unlikely 
to retain any significant residual XLF expression and hence function. We, therefore, 
monitored DSB rejoining in 2BN cells to examine the impact of marked loss of XLF 
function in vivo. We enumerated the rate of loss of γ-H2AX foci following exposure to 3 
Gy IR in G0/G1 phase primary cells, which we have shown previously represents a 
highly sensitive to assay to monitor DSB repair in vivo (Riballo et al., 2004). We also 
included two LIG4 cell lines in our analysis for comparison (Figure 4B). Since DNA 
ligase IV is essential, all mutation changes in LIG4 cell lines are hypomorphic. One cell 
line (180BR) was derived from a patient with mild clinical features (no overt 
immunodeficiency), whilst the second line (495GOS) has clinical features of similar 
severity to the 2BN patient. 2BN cells showed slow but residual DSB rejoining that 
overlaps with that observed in the LIG4 cell lines. In contrast, a DNA Ligase IV null 
mouse embryo fibroblast (MEF) displayed almost no detectable DSB rejoining up to 72 h 
post irradiation using the same assay (Figure 4C). To examine the kinetics of rejoining in 
2BN cells, we examine additional time points and observed an approximately 3 fold 
reduced rate of rejoining (Figure 4D). These findings suggest that 2BN cells display low 
but residual DSB rejoining activity in G0/G1 phase, consistent with our in vitro findings 
that XLF enhances but is not essential for LX activity.  
 
Discussion. 
XLF, a recently identified component of the NHEJ machinery, is predicted to be 
structurally related to XRCC4 and likely represents the mammalian homologue of Nej1p, 
a protein reported to regulate NHEJ in diploid yeast (Ahnesorg et al., 2006; Buck et al., 
2006; Callebaut et al., 2006; Frank-Vaillant and Marcand, 2001; Hentges et al., 2006; 
Valencia et al., 2001). XLF interacts with LX and can promote LX ds ligation activity, 
leading to the suggestion that it represents a third partner of the LX complex (Hentges et 
al., 2006; Lu et al., 2007). However, it is currently unclear how XLF promotes ds ligation 
by LX and its precise role in NHEJ. Here, we exploit biochemical and cellular 
approaches to provide insight into the role of XLF in DSB rejoining by NHEJ. 
 XRCC4 and DNA Ligase IV form a highly stable complex (Critchlow et al., 
1997; Grawunder et al., 1997); our unpublished observations). Moreover, DNA Ligase 
IV is poorly expressed in vivo and in vitro in the absence of XRCC4 (Bryans et al., 1999; 
Critchlow et al., 1997). Conversely, although the impact is less dramatic, XRCC4 has 
reduced expression in vivo in the absence of DNA Ligase IV (Figure 1B). In contrast, 
2BN cells, which have no detectable XLF protein or residual function, have normal levels 
of XRCC4 and DNA Ligase IV, and vice versa, XLF is stable in the absence of DNA 
Ligase IV. Furthermore, the interaction of XLF with the LX complex is severely reduced 
even at moderately high ionic strength (≥ 0.3 M NaCl). Indeed, although we were able to 
co-express XLF, XRCC4 and DNA Ligase IV in insect cells, we failed to purify an intact 
complex since XLF separated from the LX complex using relatively mild purification 
procedures. Taken together, our findings demonstrate that the XLF-XRCC4-DNA Ligase 
IV relationship is not an equal partnership with XLF being a weaker binding partner of 
the tightly complexed XRCC4-DNA LigIV heterodimer.  Moreover, XLF cannot fulfil 
one of the important functions of XRCC4, namely the stabilisation and solubilisation of 
DNA Ligase IV. 
To gain insight into the mechanism underlying the ability of XLF to stimulate LX 
ds ligation, we examined its impact on LX activities. XLF stimulated LX adenylation 
activity following de-adenylation by PPi treatment, and importantly promoted re-
adenylation of LX following ligation. Among the DNA ligases, DNA ligase IV is unique 
in being poorly recharged following ligation (Wang et al., 2007). Our findings present the 
first demonstration of conditions promoting recharging of LX linked to ligation. We also 
examined the impact of XLF and ATP on ligation. XLF stimulated LX ligation in the 
absence of ATP, very likely attributable to its ability to promote end-bridging but it is 
unclear if this represents a bona fide physiological role. However, the stimulation of LX 
ds ligation by XLF in the presence of ATP is entirely consistent with an impact on 
recharging following ligation and importantly shows for the first time that recharging of 
LX can promote additional ligation. Interestingly, the DNA end binding ability of XLF 
that underlies its DNA bridging ability may help to retain LX on the DNA end following 
ligation. Thus, XLF may serve to retain and recharge LX at a ds DNA end to promote 
concerted ligation of two DNA ends. Such in situ recharging would be particularly 
beneficial for ds ligation.  
The overlapping clinical features of LIG4 syndrome and XLF-deficient patients 
were perhaps surprising given the fact that XLF stimulates but is non-essential for LX 
activity. We, therefore, examined the impact of marked loss of XLF function in vivo by 
examining the 2BN cell line. The clinical features observed in LIG4 syndrome patients, 
which include immunodeficiency, microcephaly and developmental delay, cover a range 
of severities (O'Driscoll et al., 2001; Riballo et al., 1999; van der Burg et al., 2006). One 
patient (180BR) did not display overt immunodeficiency but was identified following the 
dramatic over response to radiotherapy. We included analysis of the 180BR cell line as 
well as that derived from another LIG4 patient (495GOS) who displayed marked 
immunodeficiency and required bone marrow transplantation at an early age. The 2BN 
patient also had relatively severe immunodeficiency that necessitated bone marrow 
transplantion (Dai et al., 2003). Where analysed in detail, the residual ligation activity 
detected in mutant proteins from LIG4 syndrome patients ranges from 1 to 10%, and 
residual DNA ligase IV protein is detectable in many LIG4 cell lines (Girard et al., 2004; 
Riballo et al., 2001). The analysis of DSB rejoining in 2BN cells demonstrates that, in 
contrast to the near lack of DSB rejoining in a LigIV null cell line, there is impaired but 
residual DSB rejoining. The residual DSB rejoining in LIG4 syndrome cell lines 
compared to the defect in the LigIV null line demonstrates the impact of residual activity 
in the LIG4 patients. Thus, the hypomorphic mutations in LIG4 syndrome patients allows 
substantial residual DSB rejoining.  Interestingly, cells from the 180BR patient display a 
slightly milder defect in DSB rejoining in the γH2AX assay compared to the cell line 
from the more clinically severe, 495GOS patient (Figre 4B). The DSB repair defect in 
2BN cells lies between that observed in the two LIG4 syndrome cell lines.  Thus, despite 
the different impacts of the two proteins on ligation activity in vitro, the patient cell lines 
display overlapping DSB repair deficiencies, providing an explanation for the 
overlapping clinical features of the patients. Furthermore, although it is difficult to 
entirely rule out the impact of a low level of residual XLF activity, our results with 2BN 
cells are consistent with our biochemical findings, namely that XLF facilitates ds ligation 
by promoting recharging of LX to enhance co-ordinated ds ligation rather than relying on 
two independent ligation events. Hence, it enhances DSB rejoining around 3 fold.  
 In conclusion, our findings show that XRCC4 and DNA Ligase IV interact tightly 
as an interdependent heterodimer whereas XLF is a less tightly associated binding 
partner. Stable expression of XRCC4 and DNA Ligase IV in vivo is interdependent 
whereas expression of XLF is not influenced by expression of XRCC4 or DNA Ligase 
IV. XLF stimulates LX ligation activity in an ATP dependent and independent manner. 
The ATP-independent stimulation of LX could be a consequence of its end-bridging 
activity but the physiological relevance of this is questionable.  We provide evidence that 
the ATP-dependent stimulation of LX activity is due to the ability of XLF to promote LX 
adenylation activity following ligation, a reaction that proceeds slowly in the absence of 
XLF. These findings are consistent with our analysis of 2BN cells, which have very low, 
if any, residual XLF function and show approximately 3 fold slower DSB rejoining 
activity in vivo. Taken together our findings strongly suggest that the mechanism by 





Materials and Methods. 
Cell culture. 
Primary fibroblasts, 1BR3 (control) and 2BN (XLF-deficient), hTERT immortalised 
fibroblasts, 48BRhTERT (control) and 2BNhTERT, and SV-40 transformed human 
fibroblasts, MRC5BiVA, were grown in minimal essential medium (MEM) as described 
previously (Arlett and Cole, 1988; Dai et al., 2003). Human PreB Nalm6 (wild type) and 
N114P2 (Lig4 null) were grown in RPMI medium supplemented with 10% foetal calf 
serum (FCS), penicillin and streptomycin. Chinese hamster ovary (CHO) cells, AA8 
(wild type) and XR-1 (XRCC4 null) and mouse embryonic fibroblasts (MEFs) were 
grown in MEM, supplemented with 10% FCS, penicillin and streptomycin.  
XLF was cloned into pCI neo-n-FLAG and c-HA, originally from Promega (Madison, 
USA) and modified by Dr. E. Taylor. To introduce the 11insT mutation into XLF cDNA, 
QuickChangeR XL Site-Directed Mutagenesis kit from Stratagene was utilized 
(Cambridge, UK).  MRC5BiVA were transfected using Fugene (Roche, Burgess Hill, 
UK). 
 
Immunofluorescence and immunoblotting. 
Immunofluorescence analysis was carried out as previously described (Rothkamn and 
Löbrich, 2003). Whole cell extracts for immunobltting and immunoprecipitations were 
prepared as described previously (Ahnesorg et al., 2006). α-DNA Ligase IV and α-
XRCC4 rabbit antibodies were from Serotec (Oxford, UK).  α-XLF rabbit antibody was 
generated against bacterially expressed XLF by Eurogentec (Seraing, Belgium). α-Ku70 
goat antibody and α-cMYC (9E10) were from Santa Cruz Biotechnology (Santa Cruz, 
CA). ANTI-FLAG M2 monoclonal antibody was purchased from Sigma-Aldrich (Poole, 
UK). 6xHIS monoclonal antibody came from Clontech (Palo Alto, CA). Anti-HA 
antibody (12CA5) was from Cancer Research UK. α−γ-H2AX  mouse antibody was from 
Upstate Technology (Buckingham, UK). Anti-rabbit, anti-mouse and anti-goat secondary 
antibodies were purchased from Dako (Glostrup, Denmark).  
For in vitro transcription –translation system (TNT), pcDNA3-n-His-LIG4 (Riballo et al., 
2001), pCI neo-n-Myc-XRCC4 and pCI neo-n-FLAG-XLF (this work) were expressed 
using Promega TNT T7 Quick couple transcription/translation system (Madison, USA).  
 Purification of DNA Ligase IV-XRCC4 complexes, DNA-PK and XLF. 
The expression and purification of DNA Ligase IV-XRCC4 complexes and XLF was 
performed as described previously (Hentges et al., 2006; Marchetti et al., 2006). For XLF 
purification, the bacterial pellet was lysed in 50 mM Tris pH8, 5 mM EDTA, 400 mM 
NaCl, 1 mM DTT, 1 mM PMSF and 1% Triton X-100, followed by sonication and 
clarification by centrifugation. GST-XLF was bound to GST beads and washed with lysis 
buffer. When required, the GST tag was removed by thrombin treatment.  The protein 
was concentrated using Vivascience 0.5 ml column (Sartorius). DNA-PK was purified as 
described previously (Merkle et al., 2002).   
 
Adenylation and ligations. 
Adenylation and ligations were performed as described previously (Marchetti et al., 
2006; Riballo et al., 2001). 
 
Bridging assay for the association of two DNA molecules. 
This assay was performed as described previously (Ramsden and Gellert, 1998; Stiff et 
al., 2004).  The DNA fragment was the 445 bp pBluescript cohesive fragment used for 
ligation analysis. This substrate was labelled with a biotin group using the BrightStar 
Psoralen-Biotin Nonisotonic labelling Kit (Ambion, Warrington, UK). 
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Figure 1. XLF is dispensable for DNA ligase IV stability and is a weaker binding 
partner of the stable LX complex. 
(A) 1BR3 and 2BN primary human fibroblasts were analysed by immunofluorescence 
using antibodies against DNA Ligase IV, XRCC4 and XLF. Cells were counterstained 
with DAPI. (B) Left panel: 100 μg of whole cell extract (WCE) from control (48BRhT) 
and XLF-deficient (2BNhT) hTERT, immortalised fibroblasts were analysed by 
immunoblotting with α-DNA Ligase IV, α-XRCC4, and α-XLF antibodies. 
Immunoblots were reprobed with α-Ku70 antibody as a loading control. Panels A and B 
show that 2BN cells express normal levels of DNA Ligase IV and XRCC4 but no 
detectable XLF. Middle panel: 15 μg of human control (Nalm6) and DNA Ligase IV null 
pre-B cells (N114P2) were examined by immunoblotting. XRCC4 protein levels were 
reduced in the N114P2 cells compared to control cells but the levels of XLF were normal. 
Right panel. 60 μg of WCE from Chinese hamster ovary control (AA8) and XRCC4 
deficient (XR1) cells were analysed by immunoblotting. XR-1 cells show reduced levels 
of DNA Ligase IV. XRCC4 and XLF expression was not examined since the antibodies 
used do not cross react with the rodent protein. Previous studies have shown XR-1 cells 
have no detectable XRCC4 (C) MRC5BIVA cells were transiently transfected with N-
terminal FLAG-tagged XLF (F-XLF) or empty vector (F). 500 μg of WCE were 
incubated with α-FLAG antibodies and the immunoprecipitates analysed with α-DNA 
Ligase IV antibodies after washing with buffer containing 0.12, 0.5 or 1 M NaCl. The 
blots were also analysed with α-FLAG antibodies to verify the level of XLF 
immunoprecipitated (bottom panel). The interaction between XLF and LX is reduced at 
0.5M NaCl and abolished at 1M NaCl. (D) His-LigIV, Myc-XRCC4 and FLAG-XLF 
were expressed individually in an in vitro transcription and translation (TNT) system in 
the presence of S35methionine, mixed and proteins were immunoprecipitated using α-
MYC antibodies. Immunoprecipitates were washed in 0.12 or 1 M NaCl. The samples 
washed with 1 M NaCl have distorted (wider lanes). No FLAG-XLF was detected at 1 M 
NaCl. 
 
Figure 2. XLF stimulates Ligase IV re-adenylation following ligation. 
(A) LX complexes were treated with pyrophosphate (PPi) for 15 min at room temperature 
(RT). Following dialysis to remove PPi, 1 pmol LX was incubated with α-32P-ATP in the 
presence or absence of 5 pmols XLF. XLF stimulated the LX adenylation activity 2.5 
fold. Results represent the average and SE of two experiments. (B) LX was treated with 
PPi to de-adenylate LigIV. Following dialysis, 1 pmol LX was incubated with α-32P-
ATP, with or without 30 pmols XLF and 0.2 pmols DNA ends (445 bp ds pBluescript 
fragment). The level of LX adenylation was decreased in the presence of DNA, 
suggesting that ligation may cause LX de-adenylation. (C) 1 pmol LX was incubated 
with 0.2 pmols DNA ends (445 bp fragment) for 15 min to allow ligation and hence de-
adenylation.  α-32P-ATP was then added in the presence or absence of 5 pmols XLF and 
samples were examined for adenylate complex formation. XLF enhanced the rate of 
adenylate complex formation ~3 fold. Whether XLF was present or absent during the pre-
incubation step did not change the level of adenylate complex formation. Results are the 
average and SE of two experiments. Similar findings have been observed in additional 
experiments using a range of conditions. D) Samples were treated as in C and were 
examined for ligation by gel electrophoresis. Ligation occurred during the pre-incubation 
step and peaked by 15 mins. The gel shown is representative of three independent 
experiments (E) 0.2 pmols LX were incubated with 0.8 pmols DNA ends in the presence 
or absence of 1 pmol XLF without ATP for 15 mins and samples were examined for 
ligation. The presence of XLF did not impact upon the level of ligation. (F) 2 mg WCE 
from human pre-B control cells (Nalm6) were immunoprecipitated with α-XRCC4 
antibodies and washed in buffer containing 1 or 0.12 M NaCl. Samples were treated with 
or without PPi in the presence or absence of ~35 pmols DNA ends prior to examination 
for adenylate complex formation. LX-αAMP is the adenylated LX complex. 
Immunoprecipitated samples were subjected to Western blot analysis using α-DNA 
Ligase IV antibodies to assess protein levels. The graph shows arbitrary units of intensity 
of adenylation, normalised to protein levels. The results shown are representative of two 
experiments. 
 
Figure 3. XLF stimulates LX double stranded ligation in an ATP dependent and 
independent manner.  
(A) 125 fmols LX complex were incubated with 60 fmols 5’-32P-end-labelled DNA 
fragment (445bp) and increasing amounts of XLF. The ligation products were analysed 
by gel electrophoresis. The far-left panel shows substrate ligated by T4-ligase and non-
ligated substrate as controls. XLF stimulated LX ligation activity (B) Increasing amounts 
of LX complexes were incubated with or without 17 pmols of GST-XLF in the absence 
(left panel) or presence (right panel) of ATP and 60 fmols 5’-32P-end-labelled substrate. 
No multimers are formed in the absence of XLF using this amount of LX. XLF 
stimulated LX ligation in the absence of ATP (left panel) and further stimulation was 
observed in the presence of ATP (right panel). (C) 25 fmols 5’-32P-end-labelled 445 bp 
substrate, 100 fmols biotinylated 445 bp substrate, 0.65 pmols DNA-PK and/or 17 pmols 
GST-XLF were incubated at RT for 15 min as indicated. The biotinylated substrate was 
pulled down using streptavidin beads and the presence of co-associated radioactivity was 
quantitated. 17 pmols GST-XLF shows the same level of bridging as endogenous 0.65 
pmols DNA-PK. The results represent the mean and SD of 3 experiments (D) 5 fmols LX 
complexes were incubated with or without 15 pmols XLF and 60 fmols 5’-32P-end-
labelled 445 bp DNA fragment as indicated. Ligation was estimated at time points 
shown. Little ligation occurred in the absence of XLF (diamonds). XLF stimulated 
ligation in the absence of ATP but an increase in the maximum level of ligation was 
achieved in the presence of XLF and ATP. All ligation assays are representative of a 
single experiment but similar results have been observed in at least two additional 
experiments. 
 
Figure 4. 2BN cells show a 3-fold reduced rate of DSB rejoining. (A) C-HA-XLFWT 
(XLF), C-HA-XLF11insT (11insT) and empty vector (HA) were transfected into 
MRC5BIVA cells. XLF was immunoprecipitated from 500 μg whole cell extract using 
α-HA antibodies. 50 μg WCE and a-HA immunoprecipitates (HA-IP) were analysed with 
α-HA or α-XLF antibodies. A smaller product could not be detected in cells transfected 
with either XLF or 11insT-XLF. (B) Human primary fibroblasts from control (1BR3), 
XLF-deficient (2BN) and LIG4 syndrome patients (180BR and 495BR) were analysed by 
immunofluorescence for the rate of loss of γ-H2AX foci after exposure to 3 Gy IR using 
α-γ-H2AX antibody. Results are the mean and SD of three experiments. The rate of DSB 
repair in 2BN cells is similar to that of the LIG4 syndrome cell lines. (C) The rate of 
DSB repair following 3 Gy IR was also analyzed in mouse embryonic fibroblasts (MEFs) 
defective in DNA Ligase IV (LigIV-/-p53-/-) as in B. Compared with control MEFs, the 
LigIV-/-p53-/- MEFs show no detectable rejoining up to 72 hours post irradiation (3 Gy). 
(D) Quantification of DSB rejoining over the first 6 hours following 3 Gy IR. The rate of 
repair in 1BR3 cells was approximately 5.7 DSBs per hour while 2BN cells only repaired 
2.1 DSBs per hour.  
 




